Abstract
<p class="Abstract">We tried a new method of prostate cancer treatment by inducing<em> in vitro</em> differentiation which resulted in reduction of cancer cells growth. A protein kinase inhibitor, midostaurin's ability to trigger the human prostate cancer cell line, DU145 to segregate into nerve cells was studied. Midostaurin (100 nM) suppressed the growth of DU145 cells but without change in the number of dead cells. Midostaurin started to extend neurites on DU145 cells after 24 hours and differentiated into nerve cells by 72 hours. The microtubule was stabilized by tau protein and its mRNA expression showed time-dependent increase in midostaurin-treated DU145 cells. At the same time, the amount of acetylcholinesterase was also increased. The midostaurin-treated DU145 cells showed 40% less activity than control in the colony forming assay. The results suggests that midostaurin can induce differentiation of DU145 cells into nerve cells.</p><p> </p>
Highlights
Prostate cancer in men is the major type of cancers which counts for 27% of all the cancer cases diagnosed
At 100 nM concentration, midostaurin totally inhibited the growth of DU145 cells in one week (Figure 1B)
Midostaurin, a protein kinase inhibitor has not blocked the segregation of DU145 cells inducing TPA but was able to suppress the
Summary
Prostate cancer in men is the major type of cancers which counts for 27% of all the cancer cases diagnosed. An alternate way of treatment by differentiating the cells were studied with leukemia cells (Koeffler, 1983; Hozumi, 1998). Reagents such as butyrate analogues and cytokines have shown to reduce the tumor in prostate cancer cell lines (Bang et al, 1994; Gleave et al, 1998; Mori et al, 1999; Nishimura et al, 1998) but with less success in inducing cell differentiation (Bang et al, 1994; Itayasu et al, 1998)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
